Clinical trials: Infliximab
Crohn's Disease
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently…
- Trial name
- NCT00055536
- Testing
- natalizumab
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Arthritis, Rheumatoid
The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol
The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid…
- Trial name
- NCT00246064
- Testing
- infliximab
- Volunteers
- 210 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Psoriasis, Parapsoriasis
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab.
- Trial name
- NCT00106847
- Testing
- Infliximab
- Volunteers
- 683 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
This is the trial to see how our product is similar to remicade by comparing the results of blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose and folic acid in rheumatoid…
- Trial name
- NCT01217086
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 617 people
- Sponsor
- Celltrion
Healthy
A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)
In this study, healthy volunteers will receive a single intravenous dose of either PF-06438179 or infliximab (United States) or infliximab (European Union).
- Trial name
- NCT01844804
- Testing
- PF-06438179, Remicade
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Pfizer
Colitis, Ulcerative, Crohn Disease
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants
The purpose of this study is to describe treatment patterns associated with first-line and second line biologic use (vedolizumab or other biologic) and to describe the real-world clinical effectiveness of the use (first-line and…
- Trial name
- EVOLVE-IBERIA (NCT03710486)
- Where
- 26 sites in Portugal, Spain
- Volunteers
- 409 people
- Sponsor
- Takeda
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
The primary aim of this study is allow the patients suffering from Crohn's disease , who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with…
- Trial name
- NCT00358683
- Testing
- Certolizumab pegol
- Sponsor
- UCB Pharma
Crohn's Disease
Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)
This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness for tuberculosis screening and to reinforce the patient eligibility for a treatment with…
- Trial name
- NCT00818272
- Testing
- Remicade (infliximab)
- Volunteers
- 148 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns…
- Trial name
- NCT05320159
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 17,743 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Ankylosing Spondylitis
- Trial name
- NCT02557308
- Volunteers
- 329 people
- Sponsor
- Celltrion
Crohn's Disease
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to…
- Trial name
- NCT00338650
- Testing
- adalimumab
- Where
- 97 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Abbott
Psoriasis
Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)
This is a long-term, randomized, multi-center, open-label study of infliximab treatment in adults with moderate to severe plaque-type psoriasis.
- Trial name
- NCT00358670
- Testing
- infliximab
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
- Trial name
- NCT00036439
- Testing
- Infliximab
- Volunteers
- 364 people
- Sponsor
- Centocor, Inc.
Ankylosing Spondylitis, Axial Spondyloarthritis
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial…
- Trial name
- INFAST (NCT00844805)
- Testing
- Infliximab, Naproxen
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Rheumatoid
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.
The purpose of this study is to evaluate the safety and effectiveness of Infliximab (Remicade) in patients with Rheumatoid Arthritis.
- Trial name
- NCT00036387
- Testing
- Infliximab
- Volunteers
- 347 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
RESTART C0168Z05 Rheumatoid Arthritis Study
The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition…
- Trial name
- NCT00714493
- Testing
- Infliximab
- Where
- 76 sites in United States, Austria and 8 more
- Volunteers
- 203 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Rheumatoid Arthritis
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
This Phase 3, randomized, open-label, multicenter study in rheumatoid arthritis (RA) patients with low disease activity (Disease Activity Score 28 [DAS28] >2.8 and <3.5) is being conducted to evaluate induction of remission by…
- Trial name
- NCT00521924
- Testing
- infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
This study will evaluate the efficacy, tolerability, and effect on the quality of life of infliximab in adults with moderate-to-severe psoriasis who are resistant to etanercept after 12 weeks of treatment or have failed 24 weeks…
- Trial name
- TANGO (NCT00686595)
- Testing
- Infliximab
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible…
- Trial name
- MAINTAIN (NCT01692899)
- Volunteers
- 780 people
- Sponsor
- Pfizer